Medpace vs Bio-Techne
Medpace reported revenue of $2.5 billion in fiscal 2025, 2.1 times Bio-Techne's $1.2 billion in fiscal 2026. Medpace's revenue grew 20.0% in its latest year, and Bio-Techne's fell 0.4%. Medpace had an operating margin of 21.1%, against 20.7% at Bio-Techne. Free cash flow was $682 million at Medpace and $263 million at Bio-Techne. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Medpace | Bio-Techne | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $2.5B | $1.2B |
| Revenue growth | 20.0% | −0.4% |
| Revenue growth a year, last 5 years | 22.3% | 5.5% |
| Gross margin | — | 65.8% |
| Operating margin | 21.1% | 20.7% |
| Net margin | 17.8% | 15.0% |
| Free cash flow | $682M | $263M |
| Free cash flow margin | 26.9% | 21.7% |
| Return on capital | — | 9.2% |
| Net debt to EBITDA | −0.9x | −0.2x |
| Dividends and buybacks | $917M | $92M |
| Change in diluted share count | −7.8% | −1.7% |
| Last close | $676.77 | $72.69 |
| P/E at the last close | 37.6× | 62.7× |
| Insider trades, last 12 months | sold $436.7 million | sold $437,187 |
| Piotroski F-score | 4 of 8 | 9 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MedpaceBio-Techne
Operating margin
Percent of revenue
MedpaceBio-Techne
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MedpaceBio-Techne
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Medpace and Bio-Techne pages.